AKL identifies and synthesizes secondary metabolites of plant origin with proven efficacy & safety. This innovative approach greatly increases the chances of success, while reducing the probability of unexpected side effects.
The development process is led by an expert management team with a high level of technical, scientific and strategic skill.
AKL is focused on developing its lead clinical asset APPA, a novel therapeutic for inflammatory diseases where there is a high unmet need, including osteoarthritis (OA) and other complex diseases of ageing.
APPA has the potential to be a groundbreaking oral treatment for human & animal osteoarthritis.
AKL is based at the Stevenage Bioscience Catalyst, Stevenage, Herts UK.